berberine has been researched along with Cardiac Hypertrophy in 9 studies
Cardiac Hypertrophy: Enlargement of the HEART due to chamber HYPERTROPHY, an increase in wall thickness without an increase in the number of cells (MYOCYTES, CARDIAC). It is the result of increase in myocyte size, mitochondrial and myofibrillar mass, as well as changes in extracellular matrix.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study is to investigate the effect of berberine on catecholamine level (adrenaline and noradrenaline) in rats with experimental cardiac hypertrophy." | 7.72 | Effect of berberine on catecholamine levels in rats with experimental cardiac hypertrophy. ( Chan, BT; Hong, Y; Hou, J; Hui, SS, 2003) |
| "To assess the effects of berberine on cardiac hypertrophy induceded by L-thyroxine(L-Thy) in rats." | 7.72 | [Protective effect of berberine on cardiac hypertrophy induced by L-thyroxine in rats]. ( Xu, JG; Yang, J; Zhou, ZY, 2004) |
| "Cardiac hypertrophy is a maladaptive change in response to pressure overload, and is also an important risk for developing heart failure." | 5.40 | Berberine improves pressure overload-induced cardiac hypertrophy and dysfunction through enhanced autophagy. ( Chen, SL; Iqbal, J; Li, B; Li, MH; Mao, WX; Mi, QY; Wang, ZM; Xie, HG; Yang, SH; Yu, YH; Zhang, YJ, 2014) |
| " We hypothesized that CPU86017, derived from berberine, which possesses multi-channel blocking activity, could suppress inflammatory factors, resulting in inhibition of over-expression of ether-a-go-go (ERG) and an augmented incidence of ventricular fibrillation (VF) in ischaemia/reperfusion (I/R)." | 3.74 | Inflammatory factors that contribute to upregulation of ERG and cardiac arrhythmias are suppressed by CPU86017, a class III antiarrhythmic agent. ( Dai, DZ; Dai, Y; Du, RH; Tang, WH; Yi, HW, 2008) |
| "The aim of this study is to investigate the effect of berberine on catecholamine level (adrenaline and noradrenaline) in rats with experimental cardiac hypertrophy." | 3.72 | Effect of berberine on catecholamine levels in rats with experimental cardiac hypertrophy. ( Chan, BT; Hong, Y; Hou, J; Hui, SS, 2003) |
| "To assess the effects of berberine on cardiac hypertrophy induceded by L-thyroxine(L-Thy) in rats." | 3.72 | [Protective effect of berberine on cardiac hypertrophy induced by L-thyroxine in rats]. ( Xu, JG; Yang, J; Zhou, ZY, 2004) |
| "Fibrosis is a general term encompassing a plethora of pathologies that span all systems and is marked by increased deposition of collagen." | 2.53 | AMPK in cardiac fibrosis and repair: Actions beyond metabolic regulation. ( Beauloye, C; Bertrand, L; Daskalopoulos, EP; Dufeys, C; Horman, S, 2016) |
| "Pathological cardiac hypertrophy is regarded as a critical intermediate step toward the development of heart failure." | 1.42 | Smad3 Couples Pak1 With the Antihypertrophic Pathway Through the E3 Ubiquitin Ligase, Fbxo32. ( Cartwright, EJ; Chowdhury, SK; Lei, M; Liang, Q; Liu, W; Prehar, S; Tsui, H; Wang, S; Wang, X; Zi, M, 2015) |
| "Berberine treatment of palmitate-incubated H9c2 cells reduced hypertrophy, increased α-MHC expression and decreased β-MHC expression." | 1.42 | Berberine treatment prevents cardiac dysfunction and remodeling through activation of 5'-adenosine monophosphate-activated protein kinase in type 2 diabetic rats and in palmitate-induced hypertrophic H9c2 cells. ( Chang, W; Chen, L; Hatch, GM; Meng, Z; Yao, F; Yu, Y; Zhang, M, 2015) |
| "Cardiac hypertrophy is a maladaptive change in response to pressure overload, and is also an important risk for developing heart failure." | 1.40 | Berberine improves pressure overload-induced cardiac hypertrophy and dysfunction through enhanced autophagy. ( Chen, SL; Iqbal, J; Li, B; Li, MH; Mao, WX; Mi, QY; Wang, ZM; Xie, HG; Yang, SH; Yu, YH; Zhang, YJ, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (44.44) | 29.6817 |
| 2010's | 5 (55.56) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zeng, Z | 1 |
| Pan, Y | 1 |
| Wu, W | 1 |
| Li, L | 1 |
| Wu, Z | 1 |
| Zhang, Y | 1 |
| Deng, B | 1 |
| Wei, S | 1 |
| Zhang, W | 1 |
| Lin, F | 1 |
| Song, Y | 1 |
| Li, MH | 1 |
| Zhang, YJ | 1 |
| Yu, YH | 1 |
| Yang, SH | 1 |
| Iqbal, J | 1 |
| Mi, QY | 1 |
| Li, B | 1 |
| Wang, ZM | 1 |
| Mao, WX | 1 |
| Xie, HG | 1 |
| Chen, SL | 1 |
| Tsui, H | 1 |
| Zi, M | 1 |
| Wang, S | 1 |
| Chowdhury, SK | 1 |
| Prehar, S | 1 |
| Liang, Q | 1 |
| Cartwright, EJ | 1 |
| Lei, M | 1 |
| Liu, W | 1 |
| Wang, X | 1 |
| Chang, W | 1 |
| Zhang, M | 1 |
| Meng, Z | 1 |
| Yu, Y | 1 |
| Yao, F | 1 |
| Hatch, GM | 1 |
| Chen, L | 1 |
| Daskalopoulos, EP | 1 |
| Dufeys, C | 1 |
| Bertrand, L | 1 |
| Beauloye, C | 1 |
| Horman, S | 1 |
| Du, RH | 1 |
| Yi, HW | 1 |
| Dai, DZ | 2 |
| Tang, WH | 1 |
| Dai, Y | 1 |
| Hong, Y | 1 |
| Hui, SS | 1 |
| Chan, BT | 1 |
| Hou, J | 1 |
| Yang, J | 1 |
| Zhou, ZY | 1 |
| Xu, JG | 1 |
2 reviews available for berberine and Cardiac Hypertrophy
| Article | Year |
|---|---|
AMPK in cardiac fibrosis and repair: Actions beyond metabolic regulation.
Topics: Aging; Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Berberine; Cardiomegaly; Extracell | 2016 |
Vulnerable substrate and multiple ion channel disorder in a diseased heart will be new targets for antiarrhythmic therapy.
Topics: Animals; Anti-Arrhythmia Agents; Berberine; Cardiomegaly; Humans; Ion Channels; Long QT Syndrome; My | 2000 |
7 other studies available for berberine and Cardiac Hypertrophy
| Article | Year |
|---|---|
Myocardial hypertrophy is improved with berberine treatment via long non-coding RNA MIAT-mediated autophagy.
Topics: Animals; Autophagy; Berberine; Cardiomegaly; Disease Models, Animal; Down-Regulation; Male; Myocytes | 2019 |
Berberine improves pressure overload-induced cardiac hypertrophy and dysfunction through enhanced autophagy.
Topics: Animals; Arterial Pressure; Autophagy; Berberine; Blotting, Western; Body Weight; Cardiomegaly; Card | 2014 |
Smad3 Couples Pak1 With the Antihypertrophic Pathway Through the E3 Ubiquitin Ligase, Fbxo32.
Topics: Animals; Animals, Newborn; Aorta; Berberine; Cardiomegaly; Cells, Cultured; Constriction, Pathologic | 2015 |
Berberine treatment prevents cardiac dysfunction and remodeling through activation of 5'-adenosine monophosphate-activated protein kinase in type 2 diabetic rats and in palmitate-induced hypertrophic H9c2 cells.
Topics: AMP-Activated Protein Kinases; Animals; Berberine; Cardiomegaly; Cell Line; Diabetes Mellitus, Type | 2015 |
Inflammatory factors that contribute to upregulation of ERG and cardiac arrhythmias are suppressed by CPU86017, a class III antiarrhythmic agent.
Topics: Animals; Anti-Arrhythmia Agents; Antioxidants; Aspartic Acid Endopeptidases; Berberine; Cardiomegaly | 2008 |
Effect of berberine on catecholamine levels in rats with experimental cardiac hypertrophy.
Topics: Animals; Aorta, Abdominal; Berberine; Cardiomegaly; Catecholamines; Chromatography, High Pressure Li | 2003 |
[Protective effect of berberine on cardiac hypertrophy induced by L-thyroxine in rats].
Topics: Animals; Berberine; Calcium-Transporting ATPases; Cardiomegaly; Female; Male; Protein Subunits; Rats | 2004 |